La cadena de opciones muestra datos clave de las opciones de acciones de Dubber Corp a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Dubber Corp..

Dubber Corp (OTC:DUBRF) Bolsa, Cadena de Opciones

Dubber Corp Ltd operates as a cloud platform service provider. The company provides a call recording, management, and access service with new functionality. The company product includes Dubber Connect a cloud call recording and communication capture service, available through a telephony service provider. Its only segment is Technology. Geographically, the company derives a majority of its revenue from Europe.

Dubber Corp Ltd

Wolfe Research analyst Andrew Rosivach upgrades Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) from Peer Perform to Outperform.

News

Upgrades

Analyst Ratings

NMRK

Wolfe Research Upgrades Newmark Group to Outperform

D. Boral Capital analyst Jesse Sobelson maintains EON Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EONR#AMEX">EONR</a>) with a Buy and maintains $2 price target.

Price Target

EONR

D. Boral Capital Maintains Buy on EON Resources, Maintains $2 Price Target

Barrington Research analyst Patrick Sholl maintains Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) with a Outperform and maintains $25 price target.

Barrington Research Maintains Outperform on Marcus, Maintains $25 Price Target

Telsey Advisory Group analyst Joseph Feldman maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Outperform and lowers the price target from $100 to $90.

Telsey Advisory Group Maintains Outperform on Best Buy Co, Lowers Price Target to $90

<ul>
<li>Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast cancer patients, with no treatment-related discontinuations</li>
<li>Successful completion of the pivotal Phase 3 study may support Biologics License Application, Priority Review, Full Approval, and Commercialization</li>
</ul>
PHILADELPHIA and VANCOUVER, British Columbia, May 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ)), (TSX:<a href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the presentation of positive survival and clinical benefit data in three clinical poster presentations and one publish-only abstract at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3 at McCormick Place, Chicago, IL.

BCTX

BriaCell Therapeutics To Highlight Survival And Clinical Benefit Data In Three Clinical Poster Presentations And One Publish-Only Abstract At 2025 ASCO Annual Meeting

Telsey Advisory Group analyst Dana Telsey downgrades Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) from Outperform to Market Perform and lowers the price target from $240 to $120.

Downgrades

DECK

Telsey Advisory Group Downgrades Deckers Outdoor to Market Perform, Lowers Price Target to $120

Rosenblatt analyst Blair Abernethy maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $340 to $345.

ADSK

Rosenblatt Maintains Buy on Autodesk, Raises Price Target to $345

Rosenblatt analyst Kevin Cassidy maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and maintains $130 price target.

Rosenblatt Maintains Buy on Seagate Tech Hldgs, Maintains $130 Price Target

Sol-Gel Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) reported quarterly losses of $(3.20) per share. This is a 39.13 percent decrease over losses of $(2.30) per share from the same period last year. The company reported quarterly sales of $1.03 million which missed the analyst consensus estimate of $1.20 million by 14.08 percent. This is a 121.24 percent increase over sales of $466.00 thousand the same period last year.

Earnings

Earnings Misses

SLGL

Sol-Gel Technologies Q1 EPS $(3.20) Vs. (2.30) Prior Year, Sales $1.03M Miss $1.20M Estimate

D. Boral Capital analyst Jason Kolbert maintains Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) with a Buy and lowers the price target from $15 to $10.

NNOX

D. Boral Capital Maintains Buy on Nano X Imaging, Lowers Price Target to $10

GSK's Blenrep (Belantamab Mafodotin) Received Positive Opinion Form The EUs CHMP For Treatment Of Relapsed Or Refractory Multiple Myeloma In Adults Aged 60+

PHUN

Phunware Unveils Hospitality AI Features To Enhance Mobile Guest Engagement, Plans Next-Gen App Innovation Talks

Bank of America Corporation Announced That It Will Redeem On June 12, 2025 All CHF375,000,000 Principal Amount Outstanding Of Its 0.2525% Senior Notes, Due June 12

Legal

BABA

Alibaba Concluded Some Products May Contain 3TG From Covered Countries, But Finds No Evidence The 3TG Financed Armed Groups

PPTA

Perpetua Resources Submits Formal Application To Export-Import Bank of the United States to Finance Stibnite Gold Project, Company Seeks $2B Financing; Aims To Boost U.S. Antimony Supply Amid Strategic Minerals Push

OKLO: 24% &#x7C; <a href="https://www.benzinga.com//node/45577517">Shares of OKLO and nuclear-linked stocks are trading higher amid report that President Trump to sign orders to boost nuclear power as soon as Friday.</a>
&nbsp;
BCAX: -36% &#x7C; <a href="https://www.benzinga.com//node/45576722">Bicara Therapeutics shares are trading lower after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.</a>
&nbsp;
IMMX: -20% &#x7C; <a href="https://www.benzinga.com//node/45577764">IMMX stock has given up its prior gain. Immix Biopharma shares were trading higher after the company announced the publication of cell therapy NXC-201 Abstract #7508, selected for oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting.</a>

Movers

Trading Ideas

BCAX

IMMX

OKLO

Market-Moving News for May 23rd

Memorandum aims to integrate IonQ's quantum technology into South Korea's high-performance computing infrastructure, fueling R&amp;D, talent development, and ecosystem growth.
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leading commercial quantum computing and networking company, today announced the signing of a memorandum of understanding (MoU) with the Korea Institute of Science and Technology Information (KISTI), a leading national science and technology research institute and supercomputing center. The memorandum marks a significant expansion of IonQ's long standing relationship with South Korea's government, academic and industry sectors, aligning efforts intended to accelerate the national development of quantum science and industry.
Under the terms of the MoU, IonQ and KISTI will collaborate in four key areas: advanced infrastructure access, education, talent and knowledge exchange as well as collaboration to expand market opportunities. The two organizations will work together with the intent to introduce quantum systems into KISTI and plan to integrate these systems with KISTI's high-performance computing (HPC) infrastructure.
IonQ and KISTI also plan to collaborate on joint initiatives for talent upskilling including internships and training programs to strengthen the quantum computing research community in South Korea.

IONQ

IonQ Signs MoU With KISTI To Integrate IonQ's Quantum Technology Into South Korea's Computing Infrastructure, Fueling R&D, Talent Development, And Ecosystem Growth

HC Wainwright &amp; Co. analyst Yi Chen maintains Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) with a Buy and lowers the price target from $15 to $12.

Comments

Dubber Corp

Dubber Corp (DUBRF) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL